Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with Short-course Radiation and mFOLFOX-6 in Rectal Cancer
NCT03503630Phase 2Active, not recruiting
- Sponsor
- Ali Shamseddine
- Start
- Jul 2018
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of avelumab in rectal cancer, sponsored by Ali Shamseddine. Primary endpoint: Pathologic Complete Response Rate at 17 weeks. Started Jul 2018; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03503630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503630.